Approval Year
| Substance Class |
Concept
|
| Record UNII |
4JEH3BL51N
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1226793-34-5
Created by
admin on Sat Jun 26 08:26:14 UTC 2021 , Edited by admin on Sat Jun 26 08:26:14 UTC 2021
|
PRIMARY | |||
|
CHEMBL3545344
Created by
admin on Sat Jun 26 08:26:14 UTC 2021 , Edited by admin on Sat Jun 26 08:26:14 UTC 2021
|
PRIMARY | |||
|
46203710
Created by
admin on Sat Jun 26 08:26:14 UTC 2021 , Edited by admin on Sat Jun 26 08:26:14 UTC 2021
|
PRIMARY | |||
|
4JEH3BL51N
Created by
admin on Sat Jun 26 08:26:14 UTC 2021 , Edited by admin on Sat Jun 26 08:26:14 UTC 2021
|
PRIMARY |
This is a non-substance concept
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE |
MINOR
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MINOR
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
TARGET -> INHIBITOR |
Full antagonist SAM-760 completed phase I trials with no adverse effects at doses of up to 50 mg daily. Pfizer terminated a phase II trial after SAM-760 30 mg/day failed to produce an improvement in cognition in patients already taking a stable dose of donepezil.
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
This is a non-substance concept